title: Managing anticoagulation in  patients receiving implantable  cardiac devices.
abstract: A substantial proportion of patients who undergo cardiac rhythm device implantation receive anticoagulation to prevent thromboembolism. Many patients have coexisting cardiovascular diseases treated with antiplatelet therapy. Anticoagulation may increase the risk of hemorrhagic complication, while withdrawal of anticoagulation may increase thromboembolic risk. In this article, we review and describe the available evidence, in order to inform best practice .
authors.affiliation: Box 263, Ward K2, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK.
authors.forename: Neil
authors.initials: N
authors.lastname: Mangrolia
authors.forename: Vikrant
authors.initials: V
authors.lastname: Nayar
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Pugh
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects*; D016063:Blood Loss, Surgical / Q000517:prevention & control; D017147:Defibrillators, Implantable; D019317:Evidence-Based Medicine; D006801:Humans; D010138:Pacemaker, Artificial; D019990:Perioperative Care; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D019106:Postoperative Hemorrhage / Q000453:epidemiology / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D013923:Thromboembolism / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors